Prucalopride: The evidence for its use in the treatment of chronic constipation

Core Evidence

Volumn 3, Issue 1, 2008, Pages 45-54

  Coremans, Georges ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

5 HT4 agonist; Bowel movements; Chronic constipation; Colonic transit; Gastric emptying; Laxatives; Prucalopride; Safety; Small bowel transit; Tolerance

Indexed keywords

EID: 79959351197     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.3355/ce.2008.011     Document Type: Review

References (68)

1. Altabas K, Bilic A, Juricic D, et al. The efficacy of cisapride vs placebo and diet in patient with chronic constipation. Coll Antropol. 2003;27:197-204. (Pubitemid 38376532)
2. Bassotti G, Gaburri M, Imbimbo B, et al. Colonic mass movements in idiopathic chronic constipation. Gut. 1988;29:1173-1179.
3. Bazzocchi G, Ellis J, Villanueva-Meyer J, et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology. 1990;98:686-693. (Pubitemid 20069705)
4. Bengtsson M, Ohlsson B. Retrospective study of long-term treatment with sodium picosulfate. Eur J Gastroenterol Hepatol. 2004;16:433-444.
5. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5-HT4 agonist, prucalopride in healthy humans. Gut.1999;44:482-486.
6. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie G, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation. Gastroenterology. 2001;120:354-360. (Pubitemid 32147632)
7. Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001a;423:71-83. (Pubitemid 32595730)
8. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) a colonic motility in the fasted dogs. Neurogastroenterol Motil. 2001b;13:465-472. (Pubitemid 32990146)
9. Camilleri M, Kerstens R, Ryckx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344-2354. (Pubitemid 351749158)
10. Cash BD, Chey WD. Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther. 2005;22:1047-1060. (Pubitemid 41779512)
11. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol. 2007;554:98-105. (Pubitemid 44879418)
12. Chaussade S, Minic M. Comparison of efficacy and safety of two doses different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther. 2003;17:165-172. (Pubitemid 36140447)
13. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2005;129:86-97. (Pubitemid 41002045)
14. Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology. 2006;130:657-664. (Pubitemid 43374515)
15. Coremans GE. Surgical aspects of severe chronic non-Hirschsprung constipation. Hepatogastroenterology. 1990;37:588-595.
16. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion. 2003;67:82-89. (Pubitemid 36570307)
17. Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46:522-526. (Pubitemid 30305817)
18. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am J Manag Care. 2001;7:S252-S260. (Pubitemid 32700471)
19. Damon H, Dumas P, Mion F. Impact of anal incontinence and chronic constipation on quality of life. Gastroenterol Clin Biol. 2004;28:16-20. (Pubitemid 38325598)
20. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Mol. 2008;20:99-112.
21. Dennisson C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. PharmacoEconomics. 2005;23:461-476. (Pubitemid 40994135)
22. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004;53:1520-1535. (Pubitemid 39272827)
23. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16:603-612. (Pubitemid 34214542)
24. Di Palma JA, De Ridder PA, Orlando RC, Kolts BE, Cleveland MVB. A randomized placebo-controlled multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95:446-450. (Pubitemid 30106174)
25. Di Palma JA. Expert commentary - new developments in the treatment of constipation. Med Gen Med. 2005;7:17.
26. Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436-1441. (Pubitemid 46976282)
27. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-1580. (Pubitemid 23271409)
28. El Salhy M, Norrgard O, Spinell S. Abnormal colonic endocrine cells in patients with chronic idiopathic slow transit constipation. Scand J Gastroenterol. 1999;34:1007-1011. (Pubitemid 29512870)
29. Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug RO93877 on gastrointestinal transit in healthy volunteers. Gut. 1998;42:511-516. (Pubitemid 28186568)
30. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16:1347-1356.
31. Felt-Bersma RJF, Bouchacha M, Wurzer H, Van Outryve M, Bosschert H, Van 't Klooster G. Effects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation. A double-blind, placebo-controlled, multicenter study in Europe. Gastroenterology. 1999;116:A992 (Abstract).
32. Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004;20(Suppl. 7):3-14. (Pubitemid 39657670)
33. Gershon MD, Tack J. The serotonin signalling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397-414. (Pubitemid 46127672)
34. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428-441. (Pubitemid 46701610)
35. Higgins PD, Johanson JF. Epidermiology of constipation in North America: a systemic review. Am J Gastroenterol. 2004;99:750-759. (Pubitemid 38612817)
36. Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci. 2002;47:2222-2230. (Pubitemid 35205297)
37. Johanson JF. Geographic distribution of constipation in United States. Am J Gastroenterol. 1998;93:188-191. (Pubitemid 29063964)
38. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: randomized, double-blind controlled trial. Clin Gastroenterol Hepatol. 2004;2:796-805. (Pubitemid 39200718)
39. Joslyn A, Stevens M, De Pauw M, Kerstens R. Prucalopride is safe and generally well tolerated in elderly patients with chronic constipation. Am J Gastroenterol. 2000;95:2537-2538 (Abstract).
40. Koh CE, Young CJ, Young JM, Solomon MJ. Systematic review of randomized controlled trials of the effectiveness of biofeedback for pelvic floor dysfunction. Br J Surg. 2008;95:1079-1087.
41. Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol. 2002;37:431-436. (Pubitemid 34274327)
42. 4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroentero Motil. 2005;17:366-375.
43. Legoretta A, Clark S, Marehbian J, et al. Symptoms associated with chronic gastrointestinal disorders interfere with daily living as assessed by patient reported outcomes in the primary care setting. Am J Gastroenterol. 2006;101:S490 (Abstract).
44. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360-1368.
45. Locke GR 3rd, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology. 2000;119:1766-1778. (Pubitemid 32198703)
46. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Managed Care Interface. 2006;16:43-39.
47. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am J Gastroenterol. 1999;94:609-615. (Pubitemid 29124854)
48. Miner PhB Jr, Nichols T Jr, Silvers DR, Joselyn A, Woods M. The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology. 1999;116:A-1043 (Abstract).
49. Moss AJ. The long and short of a constipation-reducing medication. N Engl J Med. 2008;358:2402-2403. (Pubitemid 351749168)
50. Moulin DE, Rykx A, Kerstens R, Vandeplassche L. Randomized, double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in patients with opioid-induced constipation. Gastroenterology. 2008;134:A-92 (Abstract).
51. Müller-Lissner S, Kamm M, Haeck P, et al. Long-term safety and tolerability of tegaserod in chronic constipation. Gastroenterology. 2004;126:A602 (Abstract).
52. Müller-Lissner SA, Kamm M, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. J Gastroenterol. 2005;100:232-242. (Pubitemid 41623292)
53. Otten MH, Schneider H, Wurzer H, et al. A double-blind, placebo-controlled evaluation of safety and efficacy of 12-weeks, twice-daily treatment with prucalopride in patients with chronic constipation. Gastroenterology. 1999;116:A1055 (Abstract).
54. Pemberton JH, Roth DM, Ilstrup DM. Evaluation and surgical treatment of severe chronic constipation. Ann Surg. 1991;214:403-411.
55. Poen AC, Felt-Bersma RJF, Van Dongen PAM, Meuwissen SGM. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999;13:1493-1497. (Pubitemid 29516262)
56. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: idiopathic slow transit constipation. Gut. 1986;27:41-48. (Pubitemid 16134474)
57. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systemic review. Am J Gastroenterol. 2005;100:936-971. (Pubitemid 40592390)
58. Rantis PC Jr, Vernava AM 3rd, Daniel GL, Longo WE. Chronic constipation - is the work-up worth the cost? Dis Colon Rectum. 1997;40:280-286. (Pubitemid 27120134)
59. Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defection. Clin Gastroenterol Hepatol. 2007;5:331-338. (Pubitemid 46401529)
60. Shelton MG. Standardized senna in the management of constipation in the puerperium. A clinical trial. S Afr Med J. 1980;57:78-80. (Pubitemid 10152949)
61. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16:759-767. (Pubitemid 34407524)
62. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958-1986. Dig Dis Sci. 1989;34:601-611.
63. Tack J, Tan G, Vandeplassche L. A randomized, double-blind, placebocontrolled trial to evaluate efficacy and safety of prucalopride in patients with chronic constipation. Gut. 2007;56:A46 (Abstract).
64. Talley NJ, Weaver AL, Zinsmeister AR, Melton L. Functional constipation and outlet delay: a population-based study. Gastroenterology. 1993;105:781-790. (Pubitemid 23249488)
65. Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm. 2007;64:1020. (Pubitemid 46801527)
66. van der Sijp JRM, Kamm MA, Nightingale JMD, et al. Disturbed gastric and small bowel transit in severe idiopathic constipation. Dig Dis Sci. 1993;38:837-844. (Pubitemid 23144625)
67. Van Outryve MJ, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up study of oral prucalopride (Resolor®) administered to patients with chronic constipation. Gastroenterology. 2008;134:A-547(T1400).
68. Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and treatment. J. Clin Gastroenterol. 1996;22:190-196. (Pubitemid 26118622)